Date | Price Target | Rating | Analyst |
---|---|---|---|
8/28/2024 | $75.00 | Overweight | Wells Fargo |
6/27/2024 | $70.00 | Sector Outperform | Scotiabank |
6/3/2024 | $75.00 | Buy | Jefferies |
1/2/2024 | $91.00 | Hold → Buy | The Benchmark Company |
12/14/2023 | $90.00 | Buy | Guggenheim |
12/13/2023 | $95.00 | Outperform | Wolfe Research |
10/10/2023 | $90.00 | Neutral → Overweight | Piper Sandler |
9/28/2023 | $83.00 | Outperform | Bernstein |
Wells Fargo initiated coverage of Exact Sciences with a rating of Overweight and set a new price target of $75.00
Scotiabank initiated coverage of Exact Sciences with a rating of Sector Outperform and set a new price target of $70.00
Jefferies resumed coverage of Exact Sciences with a rating of Buy and set a new price target of $75.00
4 - EXACT SCIENCES CORP (0001124140) (Issuer)
4 - EXACT SCIENCES CORP (0001124140) (Issuer)
4 - EXACT SCIENCES CORP (0001124140) (Issuer)
Data presented show sensitivities of 88% for colorectal cancer and 31% for advanced precancerous lesions at 90% specificity Scientific insights reflect Exact Sciences' commitment to closing the screening gap through innovation Results shared alongside evidence supporting multi-cancer early detection approach Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today announced performance data for its blood-based colorectal cancer (CRC) screening test. Results show sensitivities of 88.3% for CRC and 31.2% for advanced precancerous lesions at specificity of 90.1% for negative samples confirmed by colonoscopy. Results were presented today at the E
Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conferences and invited investors to participate by webcast. Wells Fargo Healthcare Conference, Boston Fireside chat on Wednesday, September 4, 2024 at 3:45 p.m. ET Baird Global Healthcare Conference, New York Fireside chat on Wednesday, September 11, 2024 at 10:15 a.m. ET The webcasts can be accessed in the investor relations section of Exact Sciences' website at www.exactsciences.com. About Exact Sciences Corp. A leading provider of cancer screening and diagnostic tests, Exact Sciences gives patients and h
Primary study sites Baylor Scott & White Health in Texas and Endeavor Health in Illinois aim to enroll up to 25,000 patients from diverse backgrounds, assessing the impact of MCED testing on clinical care Falcon Registry study is another step in Exact Sciences' rigorous approach to develop its future multi-biomarker class blood-based MCED test Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the first patient has joined its Multi-Cancer Early Detection (MCED) Falcon Registry Real-World Evidence (RWE) study at Baylor Scott & White, the primary study site and largest not-for-profit health system in Texas. The multi-site
Analysts' ratings for Exact Sciences (NASDAQ:EXAS) over the last quarter vary from bullish to bearish, as provided by 8 analysts. In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 6 2 0 0 0 Last 30D 1 0 0 0 0 1M Ago 2 2 0 0 0 2M Ago 0 0 0 0 0 3M Ago 3 0 0 0 0 In the assessment of 12-month price targets, analysts unveil insights for Exact Sciences, presenting an average target of $75.25, a high estimate of $85.00, and a low estimate of $70.00. A negative shift in sentiment is evident
Goldman Sachs analyst Matthew Sykes maintains Exact Sciences (NASDAQ:EXAS) with a Buy and lowers the price target from $88 to $75.
Evercore ISI Group analyst Vijay Kumar maintains Exact Sciences (NASDAQ:EXAS) with a Outperform and lowers the price target from $80 to $72.
Financing Fuels the Company's Hypergrowth to Make Elevated Care Accessible to More Patients Petrovic's Appointment Positions Imperative Care for Long Term Success and Scale Imperative Care, Inc., a medical technology company developing connected innovations to elevate care for people affected by stroke and other ischemic diseases, today announced the initial close of an oversubscribed Series E financing. The financing was led by Ally Bridge Group with participation from other existing investors, including D1 Capital Partners, AMED Ventures, Bain Capital Life Sciences, Rock Springs Capital Management LP, Innovatus Capital Partners, LLC and Pura Vida Investments. The financing also incl
Exact Sciences (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, announced today the appointment of Aaron Bloomer as chief financial officer (CFO), effective May 15, 2024. Mr. Bloomer brings to Exact Sciences more than 15 years of finance and accounting experience. He previously held leadership positions at Baxter International and 3M, where he helped improve financial results, drove operational rigor, led strategic growth initiatives, played key roles in portfolio management, acquisitions, and divestitures, and set corporate strategy and vision. At Baxter, Mr. Bloomer led corporate financial planning, reporting, and analytics (FP&A) as vice president. Prior to t
In collaboration with The Blue Hat Foundation, "Box Out Colon Cancer" offers a timely spotlight on screening and prevention for the nation's #2 cancer-related killer1 Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, is teaming up with iconic pro basketball all-star and Kentucky legend Jamal Mashburn to introduce "Box Out Colon Cancer," in observance of Colorectal Cancer Awareness Month and the most exciting time in college basketball. This national educational campaign will encourage everyone 45 and older to screen for colon cancer – a disease affecting people of all races, genders, and ethnicities – in line with American Cancer Society reco
SC 13G/A - EXACT SCIENCES CORP (0001124140) (Subject)
SC 13G/A - EXACT SCIENCES CORP (0001124140) (Subject)
SC 13G/A - EXACT SCIENCES CORP (0001124140) (Subject)
Reports record results, screened more than 1 million people with Cologuard®, raises adjusted EBITDA guidance Second quarter highlights Delivered total second quarter revenue of $699 million, an increase of 12%, or 13% on a core revenue basis, including Screening revenue of $532 million and Precision Oncology revenue of $168 million Screened more than 1 million people with Cologuard for the first time during a quarter and tested a record number of cancer patients with Oncotype DX® Advanced pipeline by generating evidence supporting molecular residual disease, multi-cancer screening, and blood-based colorectal cancer screening tests Maintains full-year 2024 revenue guidance and
Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its second quarter 2024 financial results after the close of the U.S. financial markets on July 31, 2024. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress. Second quarter 2024 webcast & conference call details Date: Wednesday, July 31, 2024 Time: 5 p.m. ET Webcast: The live webcast can be accessed at www.exactsciences.com Telephone: Domestic callers, dial 888-330-2384 International callers, dial +1 240-789
First quarter highlights Delivered total first quarter revenue of $638 million, an increase of 6% on a reported and core revenue basis, including Screening revenue of $475 million and Precision Oncology revenue of $163 million Published Cologuard Plus™ test results from pivotal BLUE-C study in The New England Journal of Medicine Maintains full-year 2024 revenue and adjusted EBITDA guidance Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company generated revenue of $638 million for the first quarter ended March 31, 2024, compared to $602 million for the same period of 2023. "The Exact Sciences team is of
10-Q - EXACT SCIENCES CORP (0001124140) (Filer)
8-K - EXACT SCIENCES CORP (0001124140) (Filer)
11-K - EXACT SCIENCES CORP (0001124140) (Filer)